Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › JBIO

Jade Biosciences

JBIO Rare disease Lead: Phase 2 11 Biotech Distilled articles ↓ 41 filings & releases ↓ Cash $107M (Jun 30, 2026) ↓ 11 verdicts ↓ 3 timing quotes ↓
ImmunologyRenal Protein

Market cap $958M 63.6M shares (10-Q, Aug 3, 2026) × $15.07 close Nov 6, 2026

Most recent annual filing: 2026-03-06

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Parade warrant corporate updateDec 31, 2026Parade warrant corporate update, Dec 31, 2026, routine
  2. JADE201 Ph1 interim2027JADE201 Ph1 interim, 2027, material
  3. JADE301 HV Ph1 interim2H 2027JADE301 HV Ph1 interim, 2H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Capital (as filed)

Cash
$107M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$354M Jun 30, 2026
Operating cash flow
−$43.7M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$461M cash, runway Q4 2028 per the update of Oct 21, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (11)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (11 calls)

Every verdict Biotech Distilled has published on Jade Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-06 Watch Jade Biosciences (JBIO) - Scientific Deep Dive for JADE101 and Pipeline Products Jade's entire valuation rests on unproven monkey-to-human translation; wait for Q2 2026 Phase 1 human PK/PD data before taking a position.
  2. 2026-05-08 Watch UPDATE: Jade Biosciences (JBIO) - The $200M ATM Lands 6 Weeks Before the Monkey-to-Human Verdict The $200M ATM adds dilution overhang to the post-readout bull case but does not change the binary; continue waiting for Q2 human PK/PD data before entering.
  3. 2026-05-27 Watch UPDATE: Jade Biosciences (JBIO) - Two First-Patient-Dosed PRs Before the Monkey-to-Human Verdict Pre-readout Phase 2 enrollment amplifies the bear case on a miss but does not change the binary; maintain watch posture until Q2 HV data prints.
  4. 2026-05-29 Watch UPDATE: Jade Biosciences (JBIO) - The Binary Has a Date: Monday, 8:00 a.m. ET With the readout three trading days away, maintain watch posture; positions entered before Monday are a pure binary gamble on monkey-to-human translation.
  5. 2026-06-02 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Monkey Translated. The Stock Dropped 11.6% Anyway. All four binary risks (translation failure, PK collapse, ADAs, safety signal) were retired by the clean Phase 1 readout; the 11.6% drop is mechanical ATM overhang, not fundamental, making the $15–18 zone asymmetric entry.
  6. 2026-06-03 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Dilution I Telegraphed, Just Not Through the Door I Expected The marketed underwritten deal concentrates dilution into a single event rather than an ATM drip, and the likely $15–17 clearing range puts post-deal entry in the asymmetric zone with retired clinical risks.
  7. 2026-06-04 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Deal Priced at the Floor of My Range The 14.7% discount deal cleared at the floor of the asymmetric entry zone; clinical risks remain retired and ~$4.70/share cash post-raise supports the risk/reward at $15–17.
  8. 2026-07-01 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Wildcard Option Got Exercised JADE301 license formalizes a third Paragon asset on identical economics; the stock has rallied 23% off the deal floor but the ATM lockup expiry on ~July 3 is the near-term technical risk to watch.
  9. 2026-08-11 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Wildcard Has a Name: Interferon-Beta JADE301 named as anti-IFN-β for dermatomyositis with Q4 2026 Phase 1 pulled forward; $461M cash and runway into Q4 2028 fortify the balance sheet, though margin of safety is thinner at $21.73 than in early June.
  10. 2026-09-30 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - The Wildcard's Monkey Data, and a Stock Below the Deal Price JADE301 monkey data is competent and on-template, but the stock breaking below the $15 deal price creates overhead supply and makes the ATM a costlier tool; science is unchanged but waiting for Q3 10-Q to check ATM activity before sizing up is prudent.
  11. 2026-10-22 Speculative buy speculative UPDATE: Jade Biosciences (JBIO) - EVERGREEN Arrives Early EVERGREEN Phase 3 pulled to Q4 2026 defuses one of the two stated AVOID triggers; science unchanged and stock back above deal price, but Q3 10-Q ATM check still warranted before adding.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (41)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 26, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

20 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)